Therapeutic Inhalation of Hydrogen Gas for Alzheimer’s Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study.
Hirohisa Ono, Yoji Nishijima, Shigeo Ohta · Pharmaceuticals (Basel, Switzerland) · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This human publication evaluated hydrogen gas in 8 patients with AD. This open-label, pilot study suggests therapeutic potential, while larger randomized, placebo-controlled studies are needed to confirm the finding.
What the Researchers Studied
To develop a disease-modifying treatment for AD through multifactorial mechanisms, an open label pilot study on H₂ treatment was conducted. (2).
How Molecular Hydrogen Was Used
Eight patients with AD inhaled 3% H₂ gas for one hour twice daily for 6 months and then followed for 1 year without inhaling H₂ gas.
What the Researchers Found
The mean individual ADAS-cog change showed significant improvement after 6 months of H₂ treatment (-4.1) vs. untreated patients (+2.6). As assessed by DTI, H₂ treatment significantly improved the integrity of neurons passing through the hippocampus vs. the initial stage.
H₂ Mechanisms / Biological Findings
The source material reviewed did not establish a specific molecular hydrogen mechanism for the reported findings.
Authors’ Conclusion
A distinct authors’ conclusion was not available in the source material reviewed by H2HUBB.
Limitations Reported by the Authors
The improvement by ADAS-cog and DTI assessments were maintained during the follow-up after 6 months (significantly) or 1 year (non-significantly). (4) Conclusions: This study suggests that H₂ treatment not only relieves temporary symptoms, but also has disease-modifying effects, despite its limitations.